Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nutra Pharma Corp. (NPHC : OTCBB)
 
 • Company Description   
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company operates through its subsidiaries and carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma currently offers several drug products for sale for the treatment of pain: Cobroxin, the over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the non-narcotic and non-addictive treatment for severe (Stage 3) pain. In addition, the Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases. Nutra Pharma Corporation is based in Boca Raton, Florida.

Number of Employees: 4

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: 1,159,625 shares
Shares Outstanding: 6,807.24 (millions)
Market Capitalization: $8.17 (millions)
Beta: 2.56
52 Week High: $0.01
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.69% 3.97%
12 Week -36.84% -30.56%
Year To Date -40.00% -26.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1537 NW 65th Ave
-
Plantation,FL 33313
USA
ph: 954-509-0911
fax: 877-895-5647
investor.relations@nutrapharma.com http://www.nutrapharma.com
 
 • General Corporate Information   
Officers
Rik J. Deitsch - Chairman; President and Chief Executive Office
Garry R. Pottruck - Director
Stewart Lonky - Director
Harold Rumph - Director
Dan Oran - Director

Peer Information
Nutra Pharma Corp. (CORR.)
Nutra Pharma Corp. (RSPI)
Nutra Pharma Corp. (CGXP)
Nutra Pharma Corp. (BGEN)
Nutra Pharma Corp. (GTBP)
Nutra Pharma Corp. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67060U208
SIC: 2833
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 6,807.24
Most Recent Split Date: 5.00 (0.03:1)
Beta: 2.56
Market Capitalization: $8.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 71.32%
vs. Previous Quarter: 36.77%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -1,940.15
09/30/21 - -3,106.21
Current Ratio
03/31/22 - -
12/31/21 - 0.03
09/30/21 - 0.02
Quick Ratio
03/31/22 - -
12/31/21 - 0.02
09/30/21 - 0.02
Operating Margin
03/31/22 - -
12/31/21 - -13,361.90
09/30/21 - -19,789.66
Net Margin
03/31/22 - -
12/31/21 - -13,361.90
09/30/21 - -19,789.66
Pre-Tax Margin
03/31/22 - -
12/31/21 - -13,399.50
09/30/21 - -19,789.66
Book Value
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Inventory Turnover
03/31/22 - -
12/31/21 - 3.49
09/30/21 - 2.57
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©